

Highlights of This Issue 309

SPECIAL FEATURES

CCR Translations

- 311 | **Targeted Isotretinoin in Neuroblastoma: Kinetics, Genetics, or Absorption**
Katherine K. Matthay
See article, p. 469

Statistics in Clinical Cancer Research

- 314 | **Tumor Burden Modeling Versus Progression-Free Survival for Phase II Decision Making**
Lee D. Kaiser

Molecular Pathways

- 320 | **Molecular Pathways: Comparing the Effects of Drugs and T Cells to Effectively Target Oncogenes**
Kathleen Anders and Thomas Blankenstein

Review

- 327 | **The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia**
Hun Ju Lee, Naval Daver, Hagop M. Kantarjian, Srdan Verstovsek, and Farhad Ravandi

HUMAN CANCER BIOLOGY

- 336 | **Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry**
Anna Marie Mulligan, Irene Raitman, Linda Feeley, Dushanthi Pinnaduwege, Linh T. Nguyen, Frances P. O'Malley, Pamela S. Ohashi, and Irene L. Andrulis

CANCER THERAPY: PRECLINICAL

- 347 | **Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74⁺ B-cell Malignancies**
Yicheng Mao, Georgia Triantafyllou, Erin Hertlein, William Towns, Matthew Stefanovski, Xiaokui Mo, David Jarjoura, Mitch Phelps, Guido Marcucci, Ly James Lee, David M. Goldenberg, Robert J. Lee, John C. Byrd, and Natarajan Muthusamy
- 357 | **BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis *In Vitro* and Shows Antitumor Activity *In Vivo* in Hematologic Malignancies**
Michelle R. Kuhne, Tanya Mulvey, Blake Belanger, Sharline Chen, Chin Pan, Colin Chong, Fei Cao, Wafa Niekro, Tom Kempe, Karla A. Henning, Lewis J. Cohen, Alan J. Korman, and Pina M. Cardarelli
- 367 | ***In Vitro* Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors**
Eleonora Fonte, Benedetta Apollonio, Lydia Scarfò, Pamela Ranghetti, Claudia Fazi, Paolo Ghia, Federico Caligaris-Cappio, and Marta Muzio
- 380 | **c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met**
Laura P. Stabile, Guoqing He, Vivian Wai Yan Lui, Cassandra Henry, Christopher T. Gubish, Sonali Joyce, Kelly M. Quesnelle, Jill M. Siegfried, and Jennifer R. Grandis
- 393 | **BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice**
Chengwen Liu, Weiyi Peng, Chunyu Xu, Yanyan Lou, Mingying Zhang, Jennifer A. Wargo, Jie Qing Chen, Haiyan S. Li, Stephanie S. Watowich, Yan Yang, Dennie Tompers Frederick, Zachary A. Cooper, Rina M. Mbofung, Mayra Whittington, Keith T. Flaherty, Scott E. Woodman, Michael A. Davies, Laszlo G. Radvanyi, Willem W. Overwijk, Gregory Lizée, and Patrick Hwu

404 **PLK1 Inhibitors Synergistically Potentiate HDAC Inhibitor Lethality in Imatinib Mesylate–Sensitive or –Resistant BCR/ABL⁺ Leukemia Cells *In Vitro* and *In Vivo***

Girija Dasmahapatra, Hiral Patel, Tri Nguyen, Elisa Attkisson, and Steven Grant

415 **Complete Regression of Metastatic Renal Cell Carcinoma by Multiple Injections of Engineered Mesenchymal Stem Cells Expressing Dodecameric TRAIL and HSV-TK**

Sae Won Kim, Su Jin Kim, Sang Hoon Park, Hyun Gul Yang, Moon Cheol Kang, Young Woo Choi, Seong Muk Kim, Sin-Soo Jeun, and Young Chul Sung

428 **Dysregulation of the Repressive H3K27 Trimethylation Mark in Head and Neck Squamous Cell Carcinoma Contributes to Dysregulated Squamous Differentiation**

Orla M. Gannon, Lilia Merida de Long, Liliana Endo-Munoz, Mehlika Hazar-Rethinam, and Nicholas A. Saunders

IMAGING, DIAGNOSIS, PROGNOSIS

442 **Variation in Precursor Lesions of Pancreatic Cancer among High-Risk Groups**

Thomas P. Potjer, Ingrid Schot, Peter Langer, Johannes T. Heverhagen, Martin N.J.M. Wasser, Emily P. Slater, Günter Klöppel, Hans M. Morreau, Bert A. Bonsing, Wouter H. de Vos tot Nederveen Cappel, Mathias Bargello, Thomas M. Gress, Hans F.A. Vasen, and Detlef K. Bartsch on behalf of the Leiden Familial Pancreatic Cancer Group and the FaPaCa registry

450 **Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors**

Makoto Endo, Hidetaka Yamamoto, Nokitaka Setsu, Kenichi Kohashi, Yusuke Takahashi, Takeaki Ishii, Kei-ichiro Iida, Yoshihiro Matsumoto, Michiyuki Hakozaiki, Mikiko Aoki, Hiroshi Iwasaki, Yoh Dobashi, Kenichi Nishiyama, Yukihide Iwamoto, and Yoshinao Oda

CANCER THERAPY: CLINICAL

462 **Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody**

Evan J. Lipson, William H. Sharfman, Charles G. Drake, Ira Wollner, Janis M. Taube, Robert A. Anders, Haiying Xu, Sheng Yao, Alice Pons, Lieping Chen, Drew M. Pardoll, Julie R. Brahmer, and Suzanne L. Topalian

469 **Adaptive Dosing Approaches to the Individualization of 13-*Cis*-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma**

Gareth J. Veal, Julie Errington, Sophie E. Rowbotham, Nicola A. Illingworth, Ghada Malik, Michael Cole, Ann K. Daly, Andrew D.J. Pearson, and Alan V. Boddy
See commentary, p. 311

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

480 **Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment**

Valentina Nardi, Peter M. Sadow, Dejan Juric, Dave Zhao, Arjola K. Cosper, Kristin Bergethon, Vanessa L. Scialabba, Julie M. Batten, Darrell R. Borger, Anthony John Iafrate, Rebecca S. Heist, Donald P. Lawrence, Keith T. Flaherty, Johanna C. Bendell, Daniel Deschler, Yi Li, Lori J. Wirth, and Dora Dias-Santagata

491 **Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy**


Heather E. Wheeler, Eric R. Gamazon, Claudia Wing, Uchenna O. Njiaju, Chidiamara Njoku, Robert Michael Baldwin, Kouros Owzar, Chen Jiang, Dorothy Watson, Ivo Shterev, Michiaki Kubo, Hitoshi Zembutsu, Eric P. Winer, Clifford A. Hudis, Lawrence N. Shulman, Yusuke Nakamura, Mark J. Ratain, and Deanna L. Kroetz for the Cancer and Leukemia Group B; Nancy J. Cox, and Mary Eileen Dolan

CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8

Matthew P. Goetz, Vera J. Suman, Tanya L. Hoskin, Michael Gnant, Martin Filipits, Stephanie L. Safgren, Mary Kuffel, Raimund Jakesz, Margaretha Rudas, Richard Greil, Otto Dietze, Alois Lang, Felix Offner, Carol A. Reynolds, Richard M. Weinshilboum, Matthew M. Ames, and James N. Ingle

RETRACTION**Retraction: Evaluation of Colon Cancer-Specific Antigen 2 as a Potential Serum Marker for Colorectal Cancer****ABOUT THE COVER**

Confocal immunofluorescent image showing the effects of the polycomb repressor complex 2 inhibitor 3-deazaneplanocin A on tumor cellularity and apoptosis in a xenotransplant model of human head and neck cancer. Immunodeficient mice were injected with a head and neck cancer cell line which was allowed to establish prior to daily treatment with 5 mg/kg DZNep. Tumor tissue has been stained with DAPI to highlight cell nuclei. Green immunofluorescence highlights the human epithelial tumor cells (AEI/III positive) and red fluorescence highlights caspase III positive dying cells. For details, see the article by Gannon and colleagues on page 428 of this issue.



Clinical Cancer Research

19 (2)

Clin Cancer Res 2013;19:309-508.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/19/2>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/19/2>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.